Should You Consider Azenta (AZTA) for Investment?

Jackson Square Partners, an investment management firm, released its “SMID-Cap Growth” Q3 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the strategy returned -7.21% (net), compared to a -0.12% for its benchmark, the Russell 2500 Growth Index. The most significant performance contributor during the quarter was information technology sector, while the healthcare sector detracted from performance. In addition, please check the fund’s top five holdings to know its best picks in 2022.

Jackson Square Partners highlighted stocks like Azenta, Inc. (NASDAQ:AZTA) in its Q3 2022 investor letter. Headquartered in Chelmsford, Massachusetts, Azenta, Inc. (NASDAQ:AZTA) provides life science products and services. On December 21, 2022, Azenta, Inc. (NASDAQ:AZTA) stock closed at $59.35 per share. One-month return of Azenta, Inc. (NASDAQ:AZTA) was 1.44%, and its shares lost 41.23% of their value over the last 52 weeks. Azenta, Inc. (NASDAQ:AZTA) has a market capitalization of $4.452 billion.

Jackson Square Partners made the following comment about Azenta, Inc. (NASDAQ:AZTA) in its Q3 2022 investor letter:

“Azenta, Inc. (NASDAQ:AZTA): market leader in the management and analysis of biological samples; on the cusp of a customer outsourcing wave that could more than double the penetration of external sample management and analysis, with optionality from a significant cash balance generated by a non-core asset sale.”

Azenta, Inc. (NASDAQ:AZTA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 22 hedge fund portfolios held Azenta, Inc. (NASDAQ:AZTA) at the end of the third quarter, which was 23 in the previous quarter.

We discussed Azenta, Inc. (NASDAQ:AZTA) in another article and shared TimesSquare Capital’s views on the company. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.